Teva EVP sells 16,195 shares under 10b5-1 plan

Teva Pharmaceutical Industries executive Matthew Shields exercised 16,195 restricted share units into ordinary shares and on the same day sold all 16,195 shares at an average price of $32.87.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Matthew Shields exercised 16,195 restricted share units into ordinary shares and on the same day sold all 16,195 shares at an average price of $32.87. The sale, which also covered tax withholding obligations from vesting, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these transactions, Shields directly holds 9,989 ordinary shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 16,195 shares ($532K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Shields Matthew

Role EVP, Global Operations

Sold 16,195 shs ($532K)

Approx. gross sale proceeds $532K

Approx. exercise cost $0.00

Approx. pre-tax spread $532K

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	16,195	$0.00	$0.00
Exercise	Ordinary Shares	16,195	$0.00	$0.00
Sale	Ordinary Shares	16,195	$32.87	$532K

Holdings After Transaction: Restricted Share Units — 32,392 contracts (Direct); Ordinary Shares — 9,989 shares (Direct)

Footnotes (5)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
4. F4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
5. F5. Restricted share units were granted on June 3, 2024, with 16,195 vested on each of June 3, 2025 and June 3, 2026, 16,195 vesting on June 3, 2027, and 16,197 vesting on June 3, 2028.

Key Figures

Shares sold: 16,195 shares Sale price: $32.87 per share Shares acquired via RSU vesting: 16,195 shares +3 more

6 metrics

Shares sold 16,195 shares Open-market sale of ordinary shares on June 3, 2026

Sale price $32.87 per share Average price for 16,195 Teva ordinary shares sold

Shares acquired via RSU vesting 16,195 shares Ordinary shares received from restricted share unit exercise

Shares held after transaction 9,989 shares Direct Teva ordinary share holdings following transactions

Rule 10b5-1 plan adoption date November 10, 2025 Pre-arranged trading plan governing June 3, 2026 sale

RSU grant date June 3, 2024 Grant date for restricted share units that vest 2025-2028

Key Terms

Rule 10b5-1 trading plan, Restricted share units, American Depositary Shares, Ordinary Shares, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Restricted share units financial

"Restricted share units were granted on June 3, 2024, with 16,195 vested"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

tax witholding obligations financial

"including shares to cover tax witholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Teva (TEVA) executive Matthew Shields report in this Form 4?

Matthew Shields reported exercising restricted share units and selling the resulting shares. He converted 16,195 restricted share units into ordinary shares, then sold all 16,195 shares in an open-market transaction, mainly to cover tax withholding tied to the vesting.

How many Teva (TEVA) shares did Matthew Shields sell and at what price?

Matthew Shields sold 16,195 Teva ordinary shares at $32.87 per share. The transaction occurred on June 3, 2026 as an open-market sale, immediately after his restricted share units vested and were converted into ordinary shares.

Were Matthew Shields’ Teva (TEVA) share sales made under a Rule 10b5-1 plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. A footnote states the transactions were effected pursuant to a plan that Shields adopted on November 10, 2025, indicating the trades were pre-arranged rather than opportunistic.

How many Teva (TEVA) shares does Matthew Shields own after these transactions?

After the transactions, Matthew Shields directly holds 9,989 ordinary shares. Before selling, he received 16,195 shares from vested restricted share units, then sold all of those shares, leaving his remaining direct holdings at 9,989 shares.

What is the vesting schedule of Matthew Shields’ Teva restricted share units?

The restricted share units were granted on June 3, 2024 with staged vesting. 16,195 units vested on each of June 3, 2025 and June 3, 2026, with 16,195 vesting on June 3, 2027 and 16,197 vesting on June 3, 2028.

How are Teva (TEVA) restricted share units settled for Matthew Shields?

Each restricted share unit gives Shields a right to one ordinary share or cash. At settlement, he receives either one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share for each unit.

Can Teva ordinary shares be held as American Depositary Shares (ADS)?

Yes, Teva’s ordinary shares may be represented by American Depositary Shares. Each ADS currently represents one ordinary share, providing an alternative way for investors and insiders to hold the company’s equity interests indirectly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shields Matthew

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/03/2026		M		16,195	A	(2)	26,184	D
Ordinary Shares(1)	06/03/2026		S(3)		16,195(4)	D	$32.87	9,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/03/2026		M			16,195	(5)	(5)	Ordinary Shares(1)	16,195	$0	32,392	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. Restricted share units were granted on June 3, 2024, with 16,195 vested on each of June 3, 2025 and June 3, 2026, 16,195 vesting on June 3, 2027, and 16,197 vesting on June 3, 2028.

	/s/ Dov Bergwerk as attorney-in-fact for Matthew Shields	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)